Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: PAREXEL | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: PAREXEL

Revenues up 11% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

PAREXEL

4Q Revenues: $585.1 million (+11%)

4Q Earnings: $40.1 million (+34%)

FY Revenues: $2.3 billion (+14%)

FY Earnings: $129.1 million (+34%)

Comments: Consolidated service revenue increased 10% in the quarter to $510.6 million, with $385.6 million in Clinical Research Services (CRS), $55.2 million in PAREXEL Consulting (PC), and $69.8 million in PAREXEL Informatics (PI). For the year consolidated service revenue was up 12% to $1.9 billion, with $1.5 billion in CRS, $216.2 million in PC, and $267.9 million in PAREXEL Informatics, Inc.The recent acquisition of the HERON Group contributed approximately $3.8 million in the quarter, and contributed $2.2 million for the fiscal year. Backlog at the end of June 2014 was $5.0 billion, up 9% for the year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters